The investment announced by the gene therapy maker Monday  gives Sanofi the right of first negotiation to license certain MeiraGTx technology in immunology neurology and metabolic disease settings. MeiraGTx is perhaps best known for its work on gene therapies for the eye but Mondays deal shows its progress elsewhere